Hironori Tanaka

List of Publications by Citations

Source: https://exaly.com/author-pdf/9437135/hironori-tanaka-publications-by-citations.pdf

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19 papers 176 sh-index g-index

20 253 sext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
19	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019 , 97, 277-285	3.6	44
18	MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. <i>Oncotarget</i> , 2016 , 7, 7207-	15 .3	39
17	Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. <i>Liver International</i> , 2010 , 30, 1027-32	7.9	15
16	Light alcohol consumption plays a protective role against non-alcoholic fatty liver disease in Japanese men with metabolic syndrome. <i>Liver International</i> , 2015 , 35, 1707-14	7.9	13
15	Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports. <i>Medicine (United States)</i> , 2020 , 99, e22782	1.8	11
14	APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism. <i>BMC Gastroenterology</i> , 2018 , 18, 24	3	9
13	Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and assessment via protein phosphorylation array. Oncotarget, 2020, 11, 2531-2542	3.3	9
12	Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis. <i>Hepatology Research</i> , 2021 , 51, 472-481	5.1	8
11	Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome. <i>BMC Gastroenterology</i> , 2016 , 16, 17	3	7
10	Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2020 , 4, 1135-1139	1.8	5
9	MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	5
8	Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome. <i>PLoS ONE</i> , 2020 , 15, e023838	8 3·7	3
7	Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2020 , 55, 1072-1086	6.9	2
6	Effects of audio and visual distraction on patientscvital signs and tolerance during esophagogastroduodenoscopy: a randomized controlled trial. <i>BMC Gastroenterology</i> , 2020 , 20, 122	3	2
5	Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma. <i>Digestion</i> , 2017 , 95, 242-251	3.6	1
4	Hepatocellular carcinoma producing granulocyte-colony stimulating factor accompanied with peritonitis carcinomatosa. <i>Acta Hepatologica Japonica</i> , 2015 , 56, 518-525	0.3	1
3	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2021 , 5, 1275-1283	1.8	1

LIST OF PUBLICATIONS

An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration. *Internal Medicine*, **2021**, 60, 1839-1845

1.1 1

Development of a renal subcapsular hematoma during angiography for diagnosis and subsequent treatment of hepatocellular carcinoma. *Clinical Journal of Gastroenterology*, **2014**, 7, 185-8

1.1